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Introduction
Low responder patients undergoing hormonal stimulation for an IVF or ICSI treatment have a reduced potential to produce an adequate number of oocytes and hence also embryos 1, 2 . Especially for patients seeking a healthy pregnancy through preimplantation genetic diagnosis (PGD), this low production of oocytes and embryo(s) in one cycle will significantly reduce their chances of success. Multiple consecutive ovarian stimulation cycles combined with serial vitrification of oocytes and embryos obtained before the actual PGD could be an option to increase the chances for these patients. Until now, only one successful case report has been presented by Chung et al. 3 where a normal birth was obtained after serial vitrification of oocytes from 5 consecutive ovarian stimulation cycles for a patient carrying reciprocal translocations.
This retrospective cohort study evaluates the efficacy of a PGD program in low responder patients after repeated ovarian stimulation and accumulation of vitrified oocytes or embryos before genetic analysis, in combination with PGD on embryos obtained from a fresh ICSI cycle.
Methods

Setting and study design
This retrospective cohort study was performed over a 30 month-period (2011-2013) at Embryolab, a private fertility treatment centre in Thessaloniki, Greece.
Cycles and patients studied
During the 30 month period 13 patients of those entering the PGD program showed to be poor responders. Patients were counselled on both options (serial oocyte or embryo vitrification) with clear explanations on pro and cons of each option. Patients selected themselves for serial oocyte or embryo vitrification. PGD patients with more than 6 oocytes or 5 embryos from their first fresh PGD cycle were excluded from the study. Study patients started a PGD cycle for one of the following indications: history of recurrent implantation failure (n=1), cystic fibrosis (n=1), X-linked microtubular myopathy (n=1), recurrent miscarriages (n=5), Duchene muscular dystrophy (n=1), chromosomal translocation (n=1) and high sperm aneuploidy (n=1). Baseline characteristics for patients were mean age of 35,2 years; mean antral follicle count of 7; mean body mass index of 24,6 kg/m 2 and a mean FSH on day 2 of cycle: 7,43 IU.
Ovarian stimulation of patients
Patient's ovarian stimulation protocol consisted of a standard downregulation protocol or antagonist protocol 4 . Hormonal stimulation treatment showed these patients to be poor responders and very few oocytes could be harvested at the time of the first oocyte collection. Following counseling, couples opted for serial vitrification of oocytes (group A) or embryos (group B) from repeat ovarian stimulation cycles. Allocation to either group was based on the outcome of a medical counseling session with the patient. One to two extra hormonal stimulation cycles were initiated to obtain an accumulated minimum of 6 mature oocytes (group A) or alternatively of 5 embryos (group B) for each patient.
IVF Laboratory protocols
Oocyte collection was carried out 36 hours post-hCG administration. Fresh semen samples were prepared by density gradient centrifugation and one wash step (Quinn's Advantage Sperm Washing Medium, Sage). ICSI was performed according to standard procedures 5 . Oocytes were checked for presence of 2 ronuclei 18-22 hours post oocyte collection. Fertilised oocytes were group-cultured in 0.7 ml droplets (Cleavage medium, Sage) and embryo quality was checked daily under a microscope using a standard protocol 10 . Oocytes and day 2 embryos were vitrified and warmed using the methods described by Kuwayama et al. (Cryotop, Cryotec, http://cryotechjapan.jp/method/warming_Protocol.htm) 6 and stored in liquid nitrogen.
Pre implantation genetic diagnosis
Embryos were biopsied on day 3 of development. Three different genetic techniques were applied, depending on the indication: fluorescent in situ hybridization (FISH) 7 was used for patients suffering from X-linked microtubular myopathy, Duchene muscular dystrophy, high sperm aneuploidy or recurrent implantation failure; polymerase chain reaction (PCR) 8 was the technique used for patients at risk for offspring with cystic fibrosis. Array complete genome hybridisation techniques (aCGH) 9 were applied for patients at risk for recurrent miscarriage or for reciprocal translocations. Biopsied embryos were cultured individually in 50 μl droplets under oil (washed sterile oil, Sage, USA) until day 5 for transfer (Cleavage medium, Sage, USA). Embryo quality was checked daily under the microscope according to a standard protocol 10 .
Transfer of embryos
Embryo(s) were transferred under abdominal ultrasound guidance (Logic 400 MD) to the patient in 0.1 ml of medium (Cleavage medium, Sage) using a Wallace-(Smithsor Labotect soft catheter (Genetec). Clinical pregnancy was defined as the presence of a gestational sac with fetal heartbeat by ultrasound imaging at 8-10 weeks after embryo transfer.
Laboratory quality
The IVF laboratory at Embryolab has ISO 9001:2000 accreditation (2007) and has been assessed in accordance to ISO 15189-2007.
Given the retrospective nature and lack of identifiable health data used in the study, no institutional review board approval was needed.
Patients signed an informed consent before the start of the treatment.
Results
During the 30 month study period, 13 patients were shown to be poor responders because of failure to produce a sufficient number
Amendments from Version 1
Patients recruitment criteria and patients demographic data are now included. More details on embryo biopsy outcomes have been supplied. Discussion section is more developed and discusses comparable high survival rates for oocytes and embryos and development and implantation rates for both fresh and vitrified embryos. Percentages in Table 1 are listed using decimal points.
See referee reports
REVISED
of oocytes or embryos to continue their PGD analysis (< 6 mature oocytes or < 5 embryos on day 2). Mean age of the patients was 35.2 years (range: 31-41 years, SD: 3.4). After medical counseling all 13 patients agreed to accumulate their oocytes or embryos by vitrification, and hence underwent repeat hormonal stimulations and oocyte collections (mean: 2.3; range 2-5 stimulations) until a sufficient number was stored (>6 mature oocytes or >5 embryos on day 2). Mean total number of oocyte collections per patient (cycles) was 2.3 (range: 2-5 cycles). Details on laboratory and clinical outcomes are listed in Table 1 . On day 3 of culture, a total of 92 embryos were biopsied and diagnosed genetically. In total 40 embryos were diagnosed as normal, 43 as abnormal and for 9 embryos no result was obtained. Mean number of biopsied embryos per patient was 7,2 (+SD: 2,1) and a mean average number of 2.1 embryos per patient were transferred. Eleven supernumerary embryos, diagnosed as being normal, were vitrified post-biopsy. One patient with a history of repeated failure of implantation had no healthy embryos available for transfer. This patient had a total of 5 embryos biopsied (2 from cryostorage and 3 fresh). Twelve out of 13 patients had an embryo transfer of a healthy embryo (92,3%) and 9 patients had a clinical pregnancy (75% clinical pregnancy rate in patients with embryo transfer). In total, 2 patients miscarried and 7 patients delivered a healthy baby (7/12; 58.3% delivery rate). Two twin pregnancies were noted; both patients had delivery of healthy babies. No frozen-thawed embryo transfer was done for any of the patients.
Discussion
Low responder patients undergoing IVF are characterised by a low number of oocytes retrieved because of suboptimal oocyte maturation, poor embryo quality, hormonal stimulation cycle or embryo transfer cancellation 2 . Cobo et al. 11 demonstrated in a prospective study that accumulation of oocytes by vitrification is a successful strategy for managing low responder patients in 'classical' IVF/ICSI treatments: delivery and cumulative delivery rates per patient were statistically higher in the low responder group (36.4%) than the low responder fresh group (23.7%). Our study could demonstrate, although on a limited number of patients, that this accumulation strategy can also be applied for a specific patient population, namely patients undergoing PGD for specific genetic diseases. Although we did not compare our outcomes to those of a control group of low responder fresh PGD patients from our center, we could demonstrate that the strategy to accumulate vitrified oocytes or embryos from consecutive hormonal stimulation cycles resulted in a sufficient number of embryos available for genetic diagnosis. As a consequence, a high percentage of patients had transfer of an embryo diagnosed to be negative for the specific genetic test (92,3%). It is evident that in order to accumulate oocytes and embryos by vitrification for the management of low responder patients, an efficient and well-established oocyte vitrification system needs to be in place. Survival rates after warming of these oocytes and embryos need to be optimal (between 80 and 100%); if this is not the case, this approach should not be offered to low responder patients. Our laboratory has high survival rates for oocytes and embryos (up to 100%) and comparable development and implantation rates for both fresh and vitrified embryos ( Although the treatment costs can be double or triple compared to one single hormonal stimulation for ICSI with PGD, the total costs of the accumulated cycles are lower because patients have to pay for only one ICSI procedure (in case of accumulation of oocytes) and only one genetic analysis combined with one embryo transfer.
Moreover, this accumulation strategy resulted in higher outcomes (58.3% delivery rate per transfer) as compared to the 24% delivery This retrospective cohort study demonstrates, although on a limited number of patients, that low responder patients in need of PGD can benefit from serial vitrification of oocytes and/or embryos after repeated ovarian stimulation cycles to improve their chances of a successful pregnancy. Future studies should address the ideal number of vitrified oocytes and/or embryos necessary in order to increase success in low responder patients undergoing PGD.
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Referee Responses for Version 1
I agree with the remarks of the first referee, furthermore I would like to add the following points for revision: Table 1: a. The numbers of normal and abnormal embryos should be specified. b. What are the definitions of clinical pregnancy rate per patient with transfer and the pregnancy rate per patient with transfer? c. How many embryos were frozen? d. How many FETs (Frozen Embryo Transfers) were done? e. All percentages should be given using decimal points.
In the discussion it is stated that a high percentage of patients had an embryo transfer of healthy embryos. In my opinion this cannot be concluded from the material presented in the manuscript. In a number of cases FISH was used on day 3 embryos, which means that not PGS, not PGD was done. This screening can only give the results for the chromosomes included in the FISH analysis, while all other chromosomes can still be aneuploid. Furthermore it is known that mosaicism can complicate analysis at day 3.
Finally the information given with respect to the costs is not detailed enough. The prices of an ICSI cycle and the PGD analysis should be given in order to come to conclusions about the financial aspects of this approach.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.
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We thank Prof. Dr. Geraedts for his questions, comments and suggestions on our manuscript. We 1.
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We thank Prof. Dr. Geraedts for his questions, comments and suggestions on our manuscript. We have listed our replies below. They will be implemented in in the final version of the manuscript. a. In total 40 embryos were diagnosed as normal, 43 as abnormal and for 9 embryos no result was obtained.
b. Clinical pregnancy is defined as the presence of a gestational sac with foetal heartbeat by ultrasound at 8-10 weeks after embryo transfer. c. Eleven supernumerary embryos, diagnosed as being normal, were frozen post-embryo transfer.
d. No Frozen embryo transfer was done for these patients. e. All percentages will be listed using decimal points.
The discussion will be rephrased and will state the following: 'As a consequence, a high percentage of patients had transfer of an embryo diagnosed to be negative for the specific genetic test (92,3%).'
Our cost calculation of the treatments was based on the following:
Traditional strategy involves repeat hormonal stimulation, repeat oocyte collection, repeat ICSI and repeat genetic diagnosis tests, each step associated with low chance for embryo transfer because of low number of oocytes collected.
Cost of the accumulation strategy includes repeat hormonal stimulation, repeat oocyte collection, repeat vitrification and storage, one warming cycle, one ICSI and one genetic diagnosis test with very good chance for an embryo transfer.
I am the co-author of the paper and have no competing interest. This is an interesting paper that addresses an important issue, but the sample size is small (13 patients) and there is relevant information lacking. I believe that this article should have the following recommendations taken into consideration:
Provide information concerning patients' baseline characteristics (as well as age, AFC and hormonal profile).
Could the authors specify how allocation was done? (Please explain "based on the outcome of a medical counselling session with the patient".)
In Methods, Ovarian stimulation of patients, in the phrase "to obtain an accumulated minimum of 6 F1000Research 2.
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In Methods, Ovarian stimulation of patients, in the phrase "to obtain an accumulated minimum of 6 oocytes" the word "mature" should be added after oocytes.
How was the cut-off of 6 mature oocytes established? Taking into account the average rates of fertilization and development to D2 embryos, isn't this cut-off too low? (It is true that with this cut-off the obtained results are good but the sample size is small…)
In Results, the phrase "until a sufficient number was stored (< 6 mature oocytes or < 5 embryos on day 2)" : the < should be a >.
One patient did not have any healthy embryos for transfer: could you please explain how many embryos were biopsied in this patient?
The total number of embryos available for PGD is given for each group, but could you provide the mean number of biopsied embryos ± SD per patient?
If multiple pregnancy rate is zero it should be specified better, if it is not zero the rate should be given.
I agree with the conclusion of the study but, in order to firmly state that vitrification for accumulation purposes in PGD cycles increases the chances of success, the next 2 points should be taken into account: Was the rate of development to day 3 embryos the same in fresh and vitrified and warmed cycles? It could be interesting to analyze the euploidy rate between embryos coming from fresh oocytes vs. vitrified + warmed oocytes; the same for fresh vs. vitrified + warmed embryos.
No competing interests were disclosed. Competing Interests:
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We would like to thank Dr. Pedro Barri for his useful comments concerning our study on the evaluation of the efficacy of a PGD program in low responder patients after repeated ovarian stimulation and accumulation of vitrified oocytes or embryos. Indeed our sample size was small, but still indicative for the usefulness of vitrification as a tool for poor responders in a PGD/PGS program. Hence we opted to describe our observations in a 'short' research article.
The following baseline characteristics will be included in the revised article: Mean Age: 35.2 years; Mean AFC:7; Mean BMI: 24.6; Mean D2 FSH: 7.43.
This retrospective cohort study was performed over a 30 month-period (2011-2013) .
